Literature DB >> 14848703

Results of long-continued cortisone administration in rheumatoid arthritis.

E W BOLAND, N E HEADLEY.   

Abstract

The administration of cortisone acetate to patients with rheumatoid arthritis usually produces prompt and often dramatic suppression of the disease manifestations. The effects of the hormone are not lasting, however, and after withdrawal relapse ensues. For sustained improvement in a chronic disease such as rheumatoid arthritis, it appears that cortisone must be given more or less continuously. This raises the question whether administration may be continued effectively and safely for long periods.Seventy-six patients with rheumatoid arthritis were given cortisone in the hope that treatment could be continued uninterruptedly for extended periods. For various clinical reasons it was necessary to discontinue treatment in 16 of these before six months, but the remaining 60 patients received the hormone uninterruptedly for six to 15 months. By using initial large suppressive amounts, then gradually reducing the dosage, and finally employing smaller maintenance doses, adequate degrees of rheumatic control were maintained in approximately two-thirds of the original 76 patients. The ability to sustain satisfactory improvement varied indirectly, in general, with the severity of the rheumatoid arthritis. The chief detriment to better results in the more severe cases was the intervention of adverse hormonal side effects which developed frequently when large or relatively large maintenance doses were required to support satisfactory improvement. Unwanted signs of hormonal excess developed in 40 per cent of cases at some time during the course of treatment. Most of them were mild or transient and disappeared or lessened when the dose of cortisone was reduced, but when the dose was reduced the degree of improvement often declined also. During prolonged cortisone therapy evidence of functional suppression of the adrenal cortices, as indicated by a decreased response of circulating eosinophils to exogenous ACTH, was present. The depression of cortical function was temporary, however. Whether irreversible damage may result when the drug is employed for longer periods cannot yet be answered.

Entities:  

Keywords:  ARTHRITIS, RHEUMATOID; CORTISONE

Mesh:

Substances:

Year:  1951        PMID: 14848703      PMCID: PMC1520676     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  8 in total

1.  Relation of the Adrenal Cortex to Rheumatic Disease: A Review of Some Recent Investigations.

Authors:  E W Boland
Journal:  Ann Rheum Dis       Date:  1950-03       Impact factor: 19.103

2.  Oral use of cortisone acetate.

Authors:  E W BOLAND; N E HEADLEY
Journal:  J Am Med Assoc       Date:  1951-01-06

3.  Physiological effects of cortisone and pituitary adrenocorticotropic hormone (ACTH) in man.

Authors:  R G SPRAGUE; M H POWER; H L MASON
Journal:  J Am Med Assoc       Date:  1950-12-16

4.  Effect of cortisone and pituitary adrenocorticotropic hormone (ACTH) on rheumatic diseases.

Authors:  P S HENCH; C H SLOCUMB; H F POLLEY; E C KENDAL
Journal:  J Am Med Assoc       Date:  1950-12-16

5.  Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions.

Authors:  P S HENCH; E C KENDALL; C H SLOCUMB; H F POLLEY
Journal:  Arch Intern Med (Chic)       Date:  1950-04

6.  Observations on the physiologic effects of cortisone and ACTH in man.

Authors:  R G SPRAGUE; M H POWER
Journal:  Arch Intern Med (Chic)       Date:  1950-02

7.  The effects of cortisone and adrenocorticotropic hormone (ACTH) on certain rheumatic diseases.

Authors:  E W BOLAND
Journal:  Calif Med       Date:  1950-06

8.  Effects of pituitary adrenocorticotropic hormone (ACTH) in rheumatoid arthritis.

Authors:  H M MARGOLIS; P S CAPLAN
Journal:  J Am Med Assoc       Date:  1951-02-10
  8 in total
  1 in total

1.  Long-term cortisone therapy in rheumatoid arthritis.

Authors:  F W HURLBURT; C E ROBINSON
Journal:  Can Med Assoc J       Date:  1954-06       Impact factor: 8.262

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.